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Abstract
The naturally occurring adeno-associated virus (AAV) isolates display diverse tissue tropisms in different hosts.
Robust cardiac transduction in particular has been reported for certain AAV strains. Successful applications of
these AAV strains in preclinical and clinical settings with a focus on treating cardiovascular disease continue to
be reported. At the same time, these studies have highlighted challenges such as cross-species variability in AAV
tropism, transduction efficiency, and immunity. Continued progress in our understanding of AAV capsid
structure and biology has provided the rationale for designing improved vectors that can possibly address these
concerns. The current report provides an overview of cardiotropic AAV, existing gaps in our knowledge, and
newly engineered AAV strains that are viable candidates for the cardiac gene therapy clinic.
Recombinant Adeno-Associated Virus Vectors
in Cardiac Gene Transfer: A Historical Perspective
Adeno-associated viruses (AAV) are nonpathogenic,helper-dependent parvoviruses with a 4.7 kb single-
stranded DNA genome. The icosahedral (T = 1) virion shell is
25 nm in diameter and comprises 60 copies of viral capsid
protein (VP) subunits. The biology of host cell entry, antige-
nicity, and tissue tropisms displayed in different hosts are
determined by clusters of amino acid residues, interdigitating
loops, surface topologies, and the three-dimensional structure
observed for different AAV capsids (Bowles et al., 2006). Since
the discovery of the first AAV strain (AAV2) in the 1960s,
several other serotypes and new AAV variants have been
isolated. A summary of current knowledge pertaining to the
biology, preclinical studies, and clinical applications of the
different AAV serotypes and pertinent literature has been
reviewed elsewhere (Agbandje-McKenna and Kleinschmidt,
2011; Mingozzi and High, 2011). The focus of the current re-
view is to provide a historical perspective of AAV as a reagent
for cardiac gene transfer, outline the biology of various car-
diotropic AAV strains, their evaluation in preclinical studies
as well as clinical trials focused on cardiac gene therapy, and
provide examples of newly engineered AAV strains available
for clinical translation.
One of the earliest studies demonstrating that recombi-
nant AAV vectors can be utilized for gene transfer in
mammalian hearts was carried out using AAV serotype 2
(Kaplitt et al., 1996). Long-term expression of the lacZ re-
porter was observed after direct intramyocardial injections
in the rat heart for 2 months and up to 6 months after in-
tracoronary infusion in adult pigs. Later studies reported
significantly higher transduction efficiencies after in-
tracoronary artery infusions of recombinant AAV2 vectors
in adult mice (Svensson et al., 1999). These pilots were
rapidly followed by preclinical studies evaluating AAV2-
mediated cardiac delivery of therapeutic transgenes such as
vascular endothelial growth factor (VEGF) in mice (Su et al.,
2000, 2002, 2004); delta-sarcoglycan in a hamster model of
dilated cardiomyopathy (Kawada et al., 2002; Li et al., 2003);
heme oxygenase-1 and superoxide dismutase in a rat model
of ischemia-induced myocardial injury (Melo et al., 2002;
Agrawal et al., 2004); human growth hormone under the
myosin heavy chain promoter in mice (Aikawa et al., 2002);
acid alpha-1,4 glucosidase in a mouse model of Pompe
disease (Fraites et al., 2002); phospholamban in mouse, rat,
and hamster models of heart failure (Hoshijima et al., 2002;
Champion et al., 2003; Iwanaga et al., 2004); dominant-
negative suppressor of cytokine signaling-1 in a model of
enterovirus-mediated cardiac injury (Yasukawa et al., 2003);
and microdystrophin delivery in the mdx mouse heart (Yue
et al., 2003). In addition to these studies, continued valida-
tion of AAV2 as a tool for cardiac gene transfer in large
animal models, including pigs (Kaspar et al., 2005), dogs
(Ferrarini et al., 2006), and baboons (McTiernan et al., 2007),
was carried out by several other groups.
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Against this backdrop of these promising preclinical
studies with AAV2, evaluation of new AAV serotypes/iso-
lates for cardiac gene transfer began about a decade ago. In
these early comparative studies, AAV1, which was isolated
as a contaminant in primate adenovirus stocks, emerged as
the lead candidate for cardiac gene transfer (Du et al., 2004).
However, at the wake of these studies, robust cardiac
transduction was also reported after direct myocardial in-
jections of AAV6, AAV7, and AAV8, all nonhuman primate
isolates (Kawamoto et al., 2005; Palomeque et al., 2007); in-
travenous administration of AAV8 (Wang et al., 2005; Zhu
et al., 2005; Palomeque et al., 2007); and intravenous admin-
istration of AAV9, a human tissue isolate (Inagaki et al., 2006;
Pacak et al., 2006) in various small animal models. Efficacy
testing of these new AAV serotypes in different animal
models of cardiac disease/heart failure was carried out over
the next few years (Su et al., 2006, 2008; Pleger et al., 2007;
Townsend et al., 2007; Andino et al., 2008; Bish et al., 2008b,c;
Bostick et al., 2008; Byrne et al., 2008; Kawase et al., 2008;
Odom et al., 2008; Raake et al., 2008).
After over a decade of evaluating recombinant AAV vec-
tors as prospective tools for cardiac gene transfer, the first
phase I/II clinical trial for treatment of heart failure using
AAV1 vectors was designed. This study involved intra-
coronary infusion of AAV1 vectors packaging the SERCA2a
gene, which encodes a major cardiac calcium cycling protein
(Hajjar et al., 2008). Progress and updates pertaining to this
clinical trial have been reported in detail (Hajjar, 2013). In the
meantime, the validation of cardiotropic AAV serotypes in
animal models of cardiac disease has continued over the past
5 years. These specific applications of recombinant AAV
vectors in cardiac gene therapy have been reviewed else-
where (Pacak and Byrne, 2011; Lai and Duan, 2012; Tang
et al., 2012; Hajjar, 2013; Scimia et al., 2013).
Cardiotropic AAV Serotypes: Vector Biology
and Species Differences
Recombinant AAV vectors utilize a diverse array of re-
ceptors for host cell binding and entry. These early events in
the infectious pathway of AAV capsids have a profound
impact on the blood circulation profile, biodistribution,
tissue uptake and clearance, as well as subsequent down-
stream events such as intracellular trafficking. Further, var-
iations in capsid structure have been shown to affect AAV
tissue tropism, antigenicity, host receptor recognition, and
efficiencies of capsid uncoating. When combined with ge-
netic variation in different preclinical animal models and
human beings, AAV biology presents a complex challenge
toward achieving effective clinical translation. Thus, a thor-
ough understanding of the molecular and cellular factors
that dictate AAV cardiotropism in different hosts is essential.
AAV1
Alpha-2,3 and alpha-2,6-linked sialic acids (SA) have been
identified as glycans essential for cell surface binding by AAV1
(Wu et al., 2006b). Coreceptors for AAV1 capsids are currently
not known. Cross-species variability in SA linkage is well
documented with human beings preferentially expressing
alpha-2,6-linked SA, while other preclinical animal models
generally overexpress alpha-2,3-linked SA (Altheide et al., 2006;
Varki and Schauer, 2009; Cohen and Varki, 2010). In addition,
humans possess an inactivating mutation in the CMP N-Acetyl
neuraminic acid hydroxylase gene, which results in the loss of
synthesis of glycolylated SA or Neu5Gc and the overexpression
of acetylated SA or Neu5Ac (Altheide et al., 2006; Varki and
Schauer, 2009; Cohen and Varki, 2010). Since AAV1 was iso-
lated as a contaminant from primate adenovirus stocks, it is
conceivable that AAV1 might have evolved to recognize
Neu5Gc and SA linkage commonly found in primates. Despite
these potential caveats and although no direct comparisons
have been made to date, cardiac transduction by AAV1 in
different large animal models appears to be quite robust. For
instance, AAV1 has been proven effective for cardiac gene
transfer through intracoronary infusion in a sheep model of
ischemic heart failure (Fargnoli et al., 2013). Another study
carried out in a porcine model demonstrated that coadminis-
tration of nitroglycerin, a vasodilator, increases AAV1 uptake
and mRNA expression in cardiac tissue (Karakikes et al., 2012).
These results support the notion that AAV1 does not readily
traverse the vascular wall and there is room for improving
cardiac gene transfer efficiency with AAV1 vectors. It is also
interesting to note that such treatment with vasodilators did
not result in increased uptake of AAV1 in lung or liver tissue.
These observations are consistent with the notion that AAV1
only appears to transduce tissues in the immediate vicinity of
the site of administration. Therefore, both intramyocardial
(intramuscular) and intracoronary routes appear optimal for
AAV1 administration. In contrast, intravenous injections of
AAV1 vectors appear to largely result in liver sequestration.
This phenomenon can possibly be attributed to binding of
AAV1 capsids by certain serum factors (see the next section on
AAV6) that could alter the biodistribution and consequently
tissue tropism. These factors should be taken into account
while evaluating AAV1 as a lead candidate for cardiac gene
therapy trials.
AAV6
Similar to AAV1, AAV6 is known to utilize alpha2,3- or
alpha2,6-linked SA as receptors for cell surface binding (Wu
et al., 2006b). However, AAV6 has the distinction of being the
only known naturally occurring strain capable of recognizing
two glycan receptors—SA and heparan sulfate (HS). Further,
epidermal growth factor receptor is a known coreceptor for
AAV6 host cell entry (Weller et al., 2010). Of the six amino acid
residues that differ between AAV6 and AAV1, a single lysine
(K531) has been shown to be impart HS binding ability to
AAV6 (Wu et al., 2006a; Ng et al., 2010; Xie et al., 2011). Three
other surface-exposed residues are thought to play a critical
role in other interactions between the AAV6 capsid and host
cells. Whether the ability of AAV6 capsids to bind dual glycan
receptors (SA and HS) confers the ability to mediate robust
and long-term myocardial gene expression has not been di-
rectly examined. In one comparative study, intracoronary in-
jections in mice revealed higher transgene expression levels in
the heart with AAV6 vectors in comparison with AAV1, 7, 8,
or 9 (Zincarelli et al., 2010). In another study comparing dif-
ferent AAV serotypes 1–8 after intramyocardial injection in
rats, AAV1 and AAV6 were found be equally robust, but less
efficient than AAV8 in transducing the heart (Palomeque et al.,
2007). Further, both AAV1 and AAV6 displayed identical
transduction profiles after intrapericardial administration in
murine hearts (Bish et al., 2008b). In general, AAV6 appears to
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have emerged as a superior vector that can achieve highly
effective cardiac gene transfer after transendocardial or in-
tracoronary injections in large animal models such as rhesus
macaques, dogs, pigs, and sheep (White et al., 2011; Gao et al.,
2011b; Bish et al., 2012; Raake et al., 2013). However, it should
also be noted that intravenous administration of AAV6 vec-
tors results in significant levels of transgene expression in the
liver and skeletal muscle. Thus, similar to AAV1, intravenous
administration of AAV6 does not appear to be optimal for
cardiac-specific gene transfer applications. Further, coadmin-
istration of vasodilators such as VEGF can improve the
transduction efficiency of AAV6, corroborating the potential
for generating mutants with an improved cardiac transduc-
tion profile (Gregorevic et al., 2004).
More recently, both AAV1 and AAV6 have been shown to
interact with canine and human galectin 3 binding protein
(G3BP), a soluble scavenger receptor (Denard et al., 2012).
This interaction is potentiated by the K531 residue unique to
AAV6. Interestingly, both AAV1 and AAV6 do not interact
with murine or macaque G3BP. Further, both AAV strains
have been shown to bind murine C-reactive protein, but not
the human counterpart (Denard et al., 2013). These findings
highlight the potential for variability in species-specific in-
teractions between AAV capsids and host proteins in gen-
eral. Whether these interactions (or lack thereof) could affect
the biodistribution and transduction profile of AAV6 in pa-
tients remains to be determined. Further, it should be noted
that preexisting humoral immunity to AAV6 (and AAV1) is
higher than that observed for AAV8 or AAV9 in both human
beings and different animal models [reviewed recently by
Rapti et al. (2012) and Louis Jeune et al. (2013)]. These studies
demonstrate that immunoglobulin and nonimmunoglobulin
neutralizing factors affecting AAV6 transduction were par-
ticularly high in canine models.
AAV9
Some of the biology of AAV9, a human isolate, has been
resolved over the past two years. Terminal galactose is the
primary cell surface receptor for AAV9 (Bell et al., 2011; Shen
et al., 2011). Coreceptors for AAV9 are currently unknown.
Comparative studies evaluating the transduction efficiencies
of different AAV serotypes after intrapericardial or in-
tramyocardial injections have revealed higher transduction by
AAV9 in the mouse and rat hearts compared with AAV1,
AAV5, AAV6, AAV7, or AAV8 after direct intramyocardial
administration (Bish et al., 2008a; Qi et al., 2010; Prasad et al.,
2011a,b; Fang et al., 2012). In contrast, transendocardial ad-
ministration of AAV6, AAV8, and AAV9 in canines revealed
that AAV9 is less efficient than AAV6 (Bish et al., 2008c). These
results have since been corroborated by another comprehen-
sive study in adult rhesus macaques, wherein AAV9 vectors
were found to mediate less efficient cardiac gene transfer
when compared with AAV6 and AAV8 after transendocardial
injection (Gao et al., 2011a). Despite these findings, recent
preclinical studies have demonstrated effective cardiac gene
transfer after intracoronary administration of AAV9 vectors in
porcine models of heart failure (Pleger et al., 2011; Fish et al.,
2013). However, it should be noted that unlike AAV6, AAV9
vectors are less cardiac-specific and display broad biodis-
tribution in off-target organs after administration. Taken to-
gether, there appears to be a lack of correlation in the cardiac
transduction profile of AAV9 observed in rodents and large
animal models. Such cross-species variability can likely be
attributed in part to the propensity for AAV9 to rapidly
spread to multiple organs after injection into any tissue type.
Studies in our lab and others have demonstrated that the
prolonged blood circulation profile of AAV9 vectors (Kotchey
et al., 2011; Shen et al., 2012) and low glycan binding avidity of
this serotype profoundly affect the cardiac transduction pro-
file (Shen et al., 2012). Whether galactose or glycan expression
levels in different organs of human and animal origin can
serve as an indicator of the cardiac gene transfer efficiency of
AAV serotypes in general remains to be determined. It is
important to note that despite these drawbacks, AAV9 is more
effective than AAV1 or AAV6 for achieving cardiac gene
transfer when administered through the intravenous route.
Further, preexisting humoral immunity to AAV9 is lower than
that observed for AAV1 or AAV6 in both human beings and
different animal models [reviewed recently by Rapti et al.
(2012) and Louis Jeune et al. (2013)]. It is critical to consider
these factors before advancing AAV9 into the cardiac gene
transfer clinic.
Engineered AAV Strains: New Vectors for the Cardiac
Gene Transfer Clinic
As discussed above, several naturally occurring AAV se-
rotypes show promise for cardiac gene transfer. AAV1 and
AAV6 appear more suitable for cardiac gene transfer through
intramyocardial, intrapericardial, or intracoronary routes,
while AAV8 and AAV9 can achieve efficient cardiac trans-
duction when administered intravenously. However, these
preclinical and clinical studies have also highlighted critical
challenges for each vector: (a) variability among different
species, (b) transduction of off-target organs such as the liver,
and (c) neutralization caused by preexisting humoral immu-
nity and non-immunoglobulin-based serum factors. Novel
mutant and chimeric AAV strains displaying improved
transduction profiles have since been engineered to address
some of these challenges. Several examples are reviewed in
detail below, and a comparative analysis of natural and en-
gineered cardiotropic AAV strains is outlined in Table 1.
Synthetic AAV2-derived strains
The earliest examples of mutant AAV vectors with an
improved cardiotropic profile were engineered using AAV2
capsids as a template (Kern et al., 2003; Muller et al., 2006;
Raake et al., 2008). These modified AAV2 strains were gen-
erated by ablating binding of AAV2 capsids to HS through
site-directed mutagenesis of critical arginine residues (R484
and/or R585). The resulting heparin binding-deficient mu-
tants displayed decreased liver tropism and continued car-
diac transduction after intravenous administration. The
cardiac transduction efficiency of liver-detargeted AAV2
mutants could be potentiated by coadministration of vaso-
dilators such as VEGF (Raake et al., 2008). Subsequent studies
in our labs engineered a hybrid liver-detargeted strain,
AAV2i8, which is capable of traversing the blood vessel
barrier and transducing cardiac and skeletal muscle tissue
with high efficiency (Asokan et al., 2010). Since then, we have
successfully carried out systemic studies resulting in robust
gene expression in primates (Asokan, Samulski and Tarantal,
unpublished). More recently, we have engineered novel





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































chimeric AAV strains by engrafting the galactose receptor
footprint from AAV9 onto AAV2i8. The resulting AAV2i8G9
strain can mediate robust cardiac gene expression compa-
rable to AAV9 after intravenous injection (Shen et al., 2013).
More importantly, AAV2i8G9 shows 50–1000-fold higher
and preferential transduction of cardiac tissue over other
major off-target organs such as liver, kidney, and spleen.
Another AAV2 mutant, dubbed AAV2.5, was the first
example of a hybrid AAV vector to proceed to clinical trials.
The AAV2.5 vector is a rationally engineered AAV strain
designed to graft the muscle tropism determinants of AAV1
onto parental AAV2 (Bowles et al., 2012). As shown in pre-
clinical studies and in a phase I clinical trial of Duchenne
muscular dystrophy, AAV2.5 is capable of robust gene
transfer in skeletal muscle. More recently, AAV2.5 and re-
lated mutants thereof were shown to display significantly
different humoral immune profiles when compared with the
AAV2 parent backbone. The ability to confer altered anti-
genicity has since been narrowed down to a single amino
acid at position 265 and appears to mediate decreased rec-
ognition by antisera when administered in mice (Li et al.,
2012). In an effort to test the importance of this domain in
alternative AAV backbones, a series of capsid variants have
been generated (AAV 1–9) and determined to mediate robust
transgene expression in numerous murine tissues. Interest-
ingly, a subclass of these mutants appears to preferentially
transduce the murine heart after intramyocardial injection
(Warischalk and Samulski, unpublished observations). An-
other related chimera, dubbed AAV3-SASTG, demonstrated
robust cardiac transduction in mice higher than AAV2.5 and
other related mutants, AAV1 as well as AAV9 vectors, after
intramyocardial administration (Piacentino et al., 2012).
Evaluation of these novel AAV1/AAV2/AAV3-derived
mutant strains in large animal models is forthcoming and
likely to provide further insight into the biology of AAV-
cardiac tissue interactions in different hosts and improved
reagents for cardiac gene transfer.
Synthetic AAV9-derived strains
Nakai and others generated a chimeric AAV1 strain capa-
ble of robust cardiac transduction in mice after intravenous
administration (Kotchey et al., 2011). The AAV1.9–6 mutant
was generated by swapping a 37 amino acid domain (of
which 11 residues differ) from the C-terminal region of the
AAV9 VP subunit onto AAV1. The mechanisms underlying
the enhanced cardiac and liver transduction of this vector
remain to be determined. Using a random mutagenesis ap-
proach, our lab discovered several novel liver-detargeted
AAV9 mutants capable of robust cardiac transduction at
levels similar to the parental AAV9 strain after intravenous
administration (Pulicherla et al., 2011). The AAV9.24,
AAV9.45, and 9.61 mutants harbored 1–2 point mutations in
residues within or adjacent to the galactose-binding region
and displayed 10–25-fold higher and preferential cardiac
transduction over liver and other off-target organs. Since then,
we have successfully carried out systemic studies resulting in
robust cardiac gene expression in a porcine model of heart
failure (Hammond and Asokan, unpublished). Zhong, Sri-
vastava, and others have recently developed a series of tyro-
sine-mutant AAV vectors that display improved gene transfer
efficiency in a wide variety of organs, including liver, muscle,
and eye (Zhong et al., 2008; Petrs-Silva et al., 2011a,b; Qiao
et al., 2012). However, it appears that single tyrosine muta-
tions in the context of AAV9 capsids were unable to enhance
cardiac transduction efficiency in two different strains of mice
(Qiao et al., 2012).
Synthetic AAV strains from combinatorial libraries
Synthetic cardiotropic AAV strains have also been obtained
from combinatorial AAV-based peptide display libraries
(Ying et al., 2010). These libraries were generated by insertion
of random peptide sequences at the N587/R588 position on
the AAV2 VP template. After intravenous injection of the
AAV peptide library in mice, hearts were excised at 3 days
after injection and subjected to super-infection with human
adenovirus 5 as organotypic cultures. Replicating AAV strains
were subjected to further rounds of PCR amplification, and
screening yielded two new cardiotropic AAV strains. Both
AAV2-PSVSPRP and AAV2-VNSTRLP yielded 50–100-fold
higher and preferential cardiac transduction over off-target
organs such as the liver and kidney. In addition, these strains
were found more effective than wild-type AAV2, the liver-
detargeted AV2/R585E mutant, and AAV9 vectors after in-
travenous administration. Additional work in preclinical large
animal models will be needed to determine whether these
targeting strategies can translate across multiple species.
A myocardium-tropic AAV strain, AAVM41, was recently
obtained by subjected DNA-shuffled libraries to directed
evolution in mice (Yang et al., 2009). The resulting chimeric
AAV capsid was derived from largely from AAV1 and 6 in-
terrupted by an *20 amino acid residue stretch from AAV8
and *200 amino acid domain derived from AAV7. AAVM41
was shown to be more efficient than AAV6 in transducing the
murine heart and as efficient as AAV9 after intravenous ad-
ministration. In addition, the mutant also demonstrated > 10-
fold attenuated tropism for liver, skeletal muscle, and other
off-target organs. Efficient rescue of cardiac function was also
demonstrated after intravenous administration of AAVM41
vectors delivering delta-sarcoglycan in a hamster cardiomy-
opathy model. Further evaluation of this chimeric AAV
portfolio in large animal models would unequivocally estab-
lish their position in the clinical pipeline.
Similar directed evolution and combinatorial engineering
strategies are likely to provide new and improved vector
candidates that can evade preexisting humoral immunity.
Early examples of such efforts include the AAV2-derived
mutants, AAV2.15 and AAV2.4, both of which contain mu-
tations at critical antigenic sites, thereby capable of evading
neutralizing antibodies in human serum (Maheshri et al.,
2006). Another approach is to mutate previously mapped
immunogenic epitopes on AAV capsids to engineer neutral-
izing antibody escape mutants (Maersch et al., 2010). The re-
cent mapping of surface-exposed antigenic epitopes using
cryo-EM (Gurda et al., 2012, 2013; Harbison et al., 2012; Lerch
et al., 2012) is likely to enable structure-driven genetic ma-
nipulation of different cardiotropic AAV serotypes to generate
novel, neutralizing antibody escape variants suitable for ad-
ministration in the presence of preexisting humoral immunity.
When combined with mutations that enhance cardiotropism
and/or cardiac gene transfer efficiency, these next-generation
AAV strains are likely to provide the cardiovascular com-
munity with improved tools for clinical gene transfer.
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